FDA Approves Groundbreaking Chikungunya Vaccine to Combat Mosquito-Borne Virus

The FDA has approved the first vaccine for chikungunya, a mosquito-borne viral disease that infects over 300,000 people annually, primarily in the global south. The approval comes as the virus has become more prevalent in the northern regions. Chikungunya can cause severe disease and long-term health problems, particularly in older adults and those with underlying medical conditions. The new vaccine, Ixchiq, will be available for vulnerable populations, including adults who have recently traveled to areas with infected mosquitoes and those at higher risk. Climate change is increasing the risk of mosquito-borne diseases like chikungunya, prompting concerns from health authorities.